☆ 4.2 Letter

Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation - Timing and conditioning regimen may be crucial

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Volume 14, Issue 8, Pages 942-943

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.bbmt.2008.05.004

Keywords

-

Categories

Hematology Immunology Transplantation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Sirolimus in combination with low-dose extended-release tacrolimus in kidney transplant recipients

Zhi-yu Zou, Lin-rui Dai, Yi-bo Hou, Chen-zhen Yu, Ren-jie Chen, Yan-yan Chen, Bin Liu, Hui-bo Shi, Nian-qiao Gong, Zhi-shui Chen, Song Chen, Sheng Chang, Wei-jie Zhang

Summary: This study found that an immunosuppressive regimen of SRL combined with low-dose ER-TAC is equally effective and safe as standard immunosuppressive regimens for renal transplant recipients, and may improve graft renal function and medication adherence.

FRONTIERS IN MEDICINE (2023)

Add to Collection

Article Hematology

Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation

Linda Arrabi, Anna Jan, Chitra Hosing, Denai R. Milton, Jason Yeh

Summary: The study examined the efficacy of transitioning from tacrolimus to sirolimus in allo-HCT patients. While the conversion showed promising resolution of acute toxicities, overall mortality rates remained high, and patients transitioning before day 55 post-allo-HCT were more likely to develop new or worsening aGVHD.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant

Malvi Savani, Kwang W. Ahn, Yue Chen, Sairah Ahmed, Amanda F. Cashen, Mazyar Shadman, Dipenkumar Modi, Farhad Khimani, Corey S. Cutler, Jasmine Zain, Jonathan E. Brammer, Andrew R. Rezvani, Timothy S. Fenske, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Mehdi Hamadani

Summary: This study compared the outcomes of reduced-intensity/non-myeloablative conditioning (RIC/NMA) and myeloablative conditioning (MAC) regimens in T-cell non-Hodgkin lymphoma (T-NHL) patients undergoing allogeneic transplant (allo-HCT). The results showed no significant differences in overall survival, non-relapse mortality, risk of progression/relapse, and therapy failure between the two regimens.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Joseph Pidala, Kelly Walton, Hany Elmariah, Jongphil Kim, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan G. Faramand, Marco L. Davila, Michael L. Nieder, Elizabeth M. Sagatys, Shernan G. Holtan, Nicholas J. Lawrence, Harshani R. Lawrence, Bruce R. Blazar, Claudio Anasetti, Said M. Sebti, Brian C. Betts

Summary: The study aimed to evaluate the safety and efficacy of combining pacritinib and sirolimus in preventing GVHD after allogeneic hematopoietic cell transplantation. The results showed that the combination treatment significantly reduced the occurrence of GVHD, preserved donor CMV immunity, and allowed timely engraftment.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Metabolic Potential of the Gut Microbiome Is Significantly Impacted by Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Mette Jorgensen, Jens C. Norgaard, Emma E. Ilett, Ramtin Z. Marandi, Marc Noguera-Julian, Roger Paredes, Daniel D. Murray, Jens Lundgren, Cameron Ross MacPherson, Henrik Sengelov

Summary: This study examines the impact of allogeneic hematopoietic stem cell transplantation (aHSCT) on the taxonomic features and metabolic functions of gut bacteria in patients with malignant hematologic disorders. The results show that there is a decrease in bacterial diversity and metabolic functions post-transplant, especially in the myeloablative group.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Immunology

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation

Jinye Zhu, Qingya Wang, Hanyun Ren, Yujun Dong, Yue Yin, Qian Wang, Zeyin Liang, Wei Liu, Qingyun Wang, Bingjie Wang, Yuan Li

Summary: This study retrospectively analyzed the effect of low-dose DAC treatment in AML/MDS patients undergoing allogeneic hematopoietic stem cell transplantation. The results showed that patients receiving DAC treatment had a significantly lower incidence of grade II-IV acute GVHD. This study provides a new treatment strategy for improving the prognosis of AML/MDS patients.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study

Yuxin Wang, Yao Sun, Jing Xie, Jiangwei Hu, Na Liu, Jianlin Chen, Botao Li, Sanchun Lan, Jingwen Niu, Lei Wang, Zhuoqing Qiao, Yu Zhang, Jing Ren, Bin Zhang, Liren Qian, Yehui Tan, Liping Dou, Yuhang Li, Liangding Hu

Summary: A Dec-containing preconditioning regimen before allo-HSCT may improve outcomes in TP53-mutant MDS patients, but further exploration of the underlying mechanism is needed.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen

Patrizia Chiusolo, Stefania Bregante, Sabrina Giammarco, Teresa Lamparelli, Lucia Casarino, Alida Dominietto, Anna Maria Raiola, Elisabetta Metafuni, Carmen Di Grazia, Francesca Gualandi, Federica Sora, Luca Laurenti, Simona Sica, Gianni Barosi, Fabio Guolo, Monica Rossi, Elena Rossi, Alessandro Vannucchi, Alessio Signori, Valerio De Stefano, Andrea Bacigalupo, Emanuele Angelucci

Summary: The combination of two alkylating agents in conditioning regimen for patients with myelofibrosis undergoing allogeneic HSCT leads to a higher rate of achieving full donor chimerism on day +30, resulting in better long term disease-free survival.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Cell & Tissue Engineering

Lung Regeneration by Transplantation of Allogeneic Lung Progenitors Using a Safer Conditioning Regimen and Clinical-grade Reagents

Irit Milman Krentsis, Ran Orgad, Yangxi Zheng, Esther Bachar Lustig, Chava Rosen, Elias Shezen, Sandeep Yadav, Bar Nathansohn Levi, Miri Assayag, Neville Berkman, Harry Karmouty Quintana, Einav Shoshan, Christa Blagdon, Yair Reisner

Summary: Transplantation of lung progenitor cells provides a potential approach for lung regeneration in patients with lung diseases. Our study demonstrates that by conditioning the recipient mice and co-infusing hematopoietic and lung progenitor cells from the same donor, successful engraftment without post-transplant immune suppression can be achieved.

STEM CELLS TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Oncology

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial

Lorenzo Lazzari, Annalisa Ruggeri, Maria Teresa Lupo Stanghellini, Sara Mastaglio, Carlo Messina, Fabio Giglio, Alessandro Lorusso, Tommaso Perini, Simona Piemontese, Magda Marcatti, Francesca Lorentino, Elisabetta Xue, Daniela Clerici, Consuelo Corti, Massimo Bernardi, Andrea Assanelli, Raffaella Greco, Fabio Ciceri, Jacopo Peccatori

Summary: The study aimed to evaluate the efficacy and safety of a conditioning regimen based on Treosulfan and fludarabine for patients with hematological diseases undergoing allo-HCT. Most patients achieved full donor chimerism at day +30 post-transplant. Overall survival at 12 years was 41.7%, progression-free survival was 31.7%, and GvHD-free/relapse-free survival was 20.9%. The overall conclusion was that the full dose of Treo (42 g/m(2)) showed myeloablative potential and a safe toxicity profile, particularly for the younger population.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial

Claire Seydoux, Michael Medinger, Sabine Gerull, Joerg Halter, Dominik Heim, Yves Chalandon, Stavroula Masouridi Levrat, Urs Schanz, Gayathri Nair, Marc Ansari, Patrick Simon, Jakob R. Passweg, Nathan Cantoni

Summary: Reversing the order of application of cyclophosphamide and busulfan in myeloablative conditioning for allo-HCT patients may lead to better outcomes. Short-term results show advantages of CyBu over BuCy in terms of liver toxicity, while long-term follow-up demonstrates lower non-relapse mortality and higher survival with CyBu compared to BuCy.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Astronomy & Astrophysics

Grain size ratio may be crucial for the fluid initiation of martian sand grains

Lin-Tao Fu

Summary: The study theoretically calculated the fluid threshold for the initiation of sand grain movement on the Martian surface, taking into account various forces including wind turbulence. It found that wind turbulence significantly impacts the movement of sand grains and provides a theoretical explanation for the observed active sand movement on Mars. The results quantitatively agree with recent findings from wind tunnel experiments.

ICARUS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cancer information overload may be a crucial determinant of adjuvant aromatase inhibitor adherence

P. Eraslan, G. Tufan

Summary: More than half of the patients (n=55, 53.4%) performed an additional online search on cancer treatment. The searcher group had higher CIO scores, depression and anxiety levels, and a higher rate of low medication adherence.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES (2022)

Add to Collection

Article Environmental Sciences

River Connectivity is Crucial for Safeguarding Biodiversity but May be Socially Overlooked. Insights From Spanish University Students

Elena Arboleya, Sara Fernandez, Laura Clusa, Eduardo Dopico, Eva Garcia-Vazquez

Summary: The study highlights the importance of river connectivity in the conservation of freshwater ecosystems, and reveals differences in the value placed on this feature by students from different academic backgrounds. While educational sciences students show a higher willingness to pay for river conservation, engineering students prioritize river connectivity less compared to other river features.

FRONTIERS IN ENVIRONMENTAL SCIENCE (2021)

Add to Collection

Article Immunology

Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia

Yimei Feng, Ting Chen, Yun Zhang, Han Yao, Ping Wang, Lu Wang, Kaniel Cassady, Zhongmin Zou, Yuqing Liu, Lu Zhao, Lei Gao, Xi Zhang, Peiyan Kong

Summary: This study examines the efficacy and tolerability of maintenance therapy with azacytidine (AZA) plus low-dose lenalidomide (LEN) to prevent relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) patients. The results show that this treatment regimen plays a significant role in preventing relapse without significantly increasing the risk of complications post-transplantation.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Letter Hematology

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm

Samantha O'Hagan Henderson, Anita Glaser, Jochen J. Frietsch, Andreas Hochhaus, Inken Hilgendorf

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

Maximilian Fleischmann, Ulf Schnetzke, Jochen J. Frietsch, Herbert G. Sayer, Karin Schrenk, Jakob Hammersen, Anita Glaser, Inken Hilgendorf, Andreas Hochhaus, Sebastian Scholl

Summary: Induction chemotherapy with intermediate-dosed cytarabine showed satisfactory response rate in AML patients, while consolidation therapy with allo-HSCT after full or reduced-intensity conditioning further improved survival, similar to outcomes reported for CPX-351.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

Samantha O'Hagan Henderson, Jochen J. Frietsch, Inken Hilgendorf, Andreas Hochhaus, Claus-Henning Koehne, Jochen Casper

Summary: Treosulfan, fludarabine, and cytarabine (Treo/Flu/AraC) conditioning regimen shows tolerable, feasible, and effective outcomes in high-risk AML, MDS, and MPN patients undergoing allogeneic SCT. The incidence of non-relapse mortality and relapse is acceptable in this heavily pre-treated population with advanced disease. Further prospective trials with larger sample sizes are needed to confirm these promising initial findings.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Maximilian Fleischmann, Sebastian Scholl, Jochen J. Frietsch, Inken Hilgendorf, Karin Schrenk, Jakob Hammersen, Florian Prims, Christian Thiede, Andreas Hochhaus, Ulf Schnetzke

Summary: This study retrospectively analyzed the outcomes of 56 acute myeloid leukemia (AML) patients treated with venetoclax from January 2019 to June 2021. The results showed that venetoclax treatment had good efficacy in both first-line treatment and relapsed or refractory AML patients. Furthermore, venetoclax might play a positive role as a salvage regimen in patients who failed conventional chemotherapy prior to or after allogeneic stem cell transplantation.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Regina Muehleck, Sebastian Scholl, Inken Hilgendorf, Karin Schrenk, Jakob Hammersen, Jochen J. Frietsch, Maximilian Fleischmann, Herbert G. Sayer, Anita Glaser, Andreas Hochhaus, Ulf Schnetzke

Summary: The Mito-FLAG salvage protocol is an effective and feasible treatment regimen for patients with r/r AML, with a high rate of achieving remission and successful transition to allogeneic hematopoietic stem cell transplantation for long-term disease-free survival.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Dietrich W. Beelen, Matthias Stelljes, Peter Remenyi, Eva-Maria Wagner-Drouet, Peter Dreger, Wolfgang Bethge, Fabio Ciceri, Friedrich Stoelzel, Christian Junghanss, Helene Labussiere-Wallet, Kerstin Schaefer-Eckart, Goetz U. Grigoleit, Christof Scheid, Francesca Patriarca, Alessandro Rambaldi, Dietger Niederwieser, Inken Hilgendorf, Domenico Russo, Gerard Socie, Ernst Holler, Bertram Glass, Jochen Casper, Gerald Wulf, Nadezda Basara, Maria Bieniaszewska, Gernot Stuhler, Mareike Verbeek, Ursula La Rocca, Juergen Finke, Fabio Benedetti, Uwe Pichlmeier, Anja Klein, Joachim Baumgart, Miroslaw Markiewicz

Summary: In older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation, treosulfan-based conditioning regimen shows better event-free survival and overall survival compared to a widely applied reduced-intensity conditioning busulfan regimen.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Biophysics

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma

Jochen J. Frietsch, Jenny Miethke, Paul Linke, Carl C. Crodel, Ulf Schnetzke, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf

Summary: The study evaluated the efficacy and safety of conditioning with Treo/Flu compared to TEAM in patients with B-cell Non-Hodgkin lymphoma (NHL) before autologous hematopoietic stem cell transplantation (auto-HSCT). The results showed no significant differences in progression-free survival, event-free survival, and overall survival between the two groups. However, the Treo/Flu group had a lower dependence on platelet transfusions, older age, and fewer infectious complications, mucositis, and stomatitis. This study highlights the potential value of Treo/Flu as an alternative conditioning regimen for elderly patients with B-cell NHL.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Biophysics

Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party

Jesus Duque-Afonso, Juergen Finke, Myriam Labopin, Charles Craddock, Rachel Protheroe, Panagiotis Kottaridis, Eleni Tholouli, Jenny L. Byrne, Kim Orchard, Urpu Salmenniemi, Inken Hilgendorf, Hannah Hunter, Emma Nicholson, Adrian Bloor, John A. Snowden, Mareike Verbeek, Andrew Clark, Bipin N. Savani, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty

Summary: This study compared the outcomes of two commonly used conditioning protocols, FluMel and FluTreo, for patients with acute myeloid leukemia. While both groups had similar overall survival rates, the FluMel group had a lower relapse incidence and slightly higher non-relapse mortality.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Long-term survival in cancer: definitions, concepts, and design principles of survivorship programs

Corinna Bergelt, Carsten Bokemeyer, Inken Hilgendorf, Thorsten Langer, Oliver Rick, Ulf Seifart, Uwe Koch-Gromus

Summary: Due to improvements in diagnostics and treatment options in hematology and oncology, the number of long-term cancer survivors in Germany is constantly increasing. However, the healthcare situation for these survivors is not satisfactory. Therefore, it is necessary to develop orientation guides and innovative survivorship programs.

BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ (2022)

Add to Collection

Article Oncology

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

Annamaria Brioli, Theresa Maria Naegler, Olaposi Yomade, Maria Madeleine Ruethrich, Sebastian Scholl, Jochen J. J. Frietsch, Inken Hilgendorf, Thomas Ernst, Herbert Gottfried Sayer, Andreas Hochhaus, Lars-Olof Muegge, Marie von Lilienfeld-Toal

Summary: This study provides a sex-disaggregated analysis of multiple myeloma patients in Germany, showing comparable survival rates between men and women, but higher toxicity of high-dose therapy in women. Additionally, women have a higher incidence of clinically relevant anaemia, which requires further investigation to identify treatable causes.

ONCOLOGY RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Roellig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Kraemer, Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim H. Bruemmendorf, Edgar Jost, Bjoern Steffen, Gesine Bug, Hermann Einsele, Dennis Goerlich, Cristina Sauerland, Kerstin Schaefer-Eckart, Stefan W. Krause, Mathias Haenel, Maher Hanoun, Martin Kaufmann, Bernhard Woermann, Michael Kramer, Katja Sockel, Katharina Egger-Heidrich, Tobias Herold, Gerhard Ehninger, Andreas Burchert, Uwe Platzbecker, Wolfgang E. Berdel, Carsten Mueller-Tidow, Wolfgang Hiddemann, Hubert Serve, Matthias Stelljes, Claudia D. Baldus, Andreas Neubauer, Johannes Schetelig, Christian Thiede, Martin Bornhaeuser, Jan M. Middeke, Friedrich Stoelzel

Summary: In this study, the impact of alloHCT on AML patients with IDH1/2 mutations was investigated. It was found that certain IDH mutational subclasses, such as IDH1 R132C and IDH2 R172K, showed a significant benefit from alloHCT in terms of overall survival (OS) and relapse-free survival (RFS) compared to chemotherapy alone. AlloHCT may have prognostic value for AML risk stratification and therapeutic decision making.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Oncology

Psychosocial distress in young adults surviving hematological malignancies: a pilot study

Andreas Wittwer, Kristin Sponholz, Jochen J. Frietsch, Paul Linke, Peter Kropp, Andreas Hochhaus, Inken Hilgendorf

Summary: Young adult cancer survivors experience psychosocial distress and have unmet needs. They often report depressive symptoms, anxiety, fear of progression, and increased psychosocial stressors. Their quality of life is lower than the general population and they have poorer outcomes. Employment is associated with lower levels of psychosocial distress, anxiety, fatigue, and better quality of life. Further longitudinal studies are needed to confirm these findings, and psycho-oncological and social support should be integrated into the aftercare of young adult cancer survivors.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Cell Biology

Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation: A study from the EBMT Cellular Therapy and Immunobiology Working Party

Pietro Crivello, Jarl E. Mooyaart, Nicolaus Kroeger, Regis Peffault de Latour, Henrik Sengeloev, Ibrahim Yakoub-Agha, Juergen Finke, Wolfgang Bethge, Peter Dreger, Victoria Potter, David Burns, Tobias Gedde-Dahl, Anne Huynh, Stephan Mielke, Matthias Eder, Claude Eric Bulabois, Edouard Forcade, A. E. C. Broers, Urpu Salmenniemi, Inken Hilgendorf, Goda Choi, Jenny Byrne, Kim Orchard, Virginie Gandemer, Eric Deconinck, Pietro Merli, Marco Andreani, Simona Pagliuca, Carmelo Gurnari, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Tobias Lenz, Christian Chabannon, Annalisa Ruggeri, Katharina Fleischhauer

HLA (2023)

Add to Collection

Article Hematology

High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Judith Schaffrath, Christina Brummer, Daniel Wolff, Udo Holtick, Nicolaus Kroger, Martin Bornhauser, Sabrina Kraus, Inken Hilgendorf, Igor-Wolfgang Blau, Olaf Penack, Christoph Wittke, Normann Steiner, David Nachbaur, Lorenz Thurner, Heidrun Hindahl, Robert Zeiser, Claus-Philipp Maier, Wolfgang Bethge, Lutz P. Muller

Summary: This retrospective study aimed to analyze the risk factors, disease course, and outcomes of COVID-19 in patients who underwent alloSCT, finding a high overall mortality rate, especially among patients treated in an ICU.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Meeting Abstract Cell Biology

HLA disease association study with more than 50,000 controls shows protective effects for HLA-B40:01 and C03:04 in NPM1-mutated AML

Elke Rucker-Braun, Bose Falk, Henning Baldauf, Carolin Massalski, Gesine Schaefer, Heidi Altmann, Juergen Sauter, Ute Solloch, Vinzenz Lange, Friedrich Stoelzel, Christoph Roellig, Moritz Jan Middeke, Malte von Bonin, Christian Thiede, Alexander H. Schmidt, Martin Bornhaeuser, Johannes Schetelig, Falk Heidenreich

HLA (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.